Akretiv Animal Health is an asset-focused development company operating at the intersection of human and animal health. We identify human life sciences assets with credible veterinary potential and build the animal-health-specific evidence, strategy and partnerships required to make those assets more valuable and transaction-ready.

Even a promising human program may be too early for an animal health buyer. It may lack target-species proof of concept, a practical veterinary formulation, regulatory clarity, a commercialization strategy or a defensible animal health valuation. Akretiv acts as an outsourced animal health development team: we evaluate the opportunity, secure an option or other defined rights, establish the target product profile and development plan, budget the work needed to reach the next inflection point, and coordinate execution.

When external capital is required, the program can be organized in a dedicated special purpose vehicle (SPV). This ring-fenced structure allows investors to evaluate and fund a specific asset while the human life sciences partner remains focused on its core human program. Akretiv seeks to monetize each animal health program through a strategic sale, license or co-development transaction at the point that offers the best available risk-adjusted outcome.